Dr. Akira Liu China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
AnHeart Therapeutics
Director of BD 
Functionality

Mr. Hanson Lo China

Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.
Company Size (Fulltime employees)
Please specify your partnering goal
We are interested in investment and licensing deals with companies developing therapeutics in a wide variety of areas, including oncology, CNS diseases, ophthalmology, and infectious diseases.
Headquartner in China
Huahai Investment Co., Ltd
Director, BD 
Functionality

Brad Loncar

Loncar Investments
CEO 

Leila Lu China

A joint venture with AstraZeneca, focusing on introducing life science companies into Wuxi and develop the biopharmaceutical industry in the city.
Website:
Www.wnd.gov.cn
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Wuxi ICampus Int'l Life Science Industrial Park
Vice Director 

iris lu China

CRO & CDMO
Partnering Objectives
Headquartner in China
GenScript biotech
品牌经理 

Lucy Lu

Kintor Pharmaceutical
CFO 

Mr. Avery Lu United States

We bring foundational science and commercial viability together for social and market impact.

We provide a human innovation ecosystem offering commercially focused support for inventors.

DEEP TECH FUNDING REINVENTED WITH SCIENCE, FOR SCIENCE

6 practice areas: AI, Robotics, Life Science, Quantum Computing, Energy, Secure Platforms & Networks
Company Size (Fulltime employees)
Please specify your partnering goal
Strategic collaboration
Headquartner in China
Aventurine Capital Management, LLC
Investment Research Lead 
Functionality

Leslie Lu China

Illumina is a provider of Next Generation Sequencing technology
Website:
www.illumina.com
Partnering Objectives
Headquartner in China
illumina
BD Manager 

Chunhua Lu China

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

Company Size (Fulltime employees)
Year of foundation
5
Headquartner in China
Biotech/Pharma Category
InnoCare
Head of Communication 

Dr. Min Lu United States

Biopharmaceutical
Website:
www.merck.com
Company Size (Fulltime employees)
Please specify your partnering goal
NA
Headquartner in China
Biotech/Pharma Category
Merck
Assoc Principal Scientist